Bring the lab
to your lobby

Employers are under more pressure than ever to protect the health and safety of their employees

Uncompromised on-site testing with the LumiraDx Platform delivers fast, accurate antigen testing. Rapidly identify contagious spreaders on the spot, reducing the risk of a local outbreak & the potential impact on your operations, helping to build employee confidence

"It’s time to change how we think about the sensitivity of testing for COVID-19."1

The benefits of uncompromised on-site testing with LumiraDx

  • Less-sensitive lateral flow antigen tests2-4 increase the risk of an infectious employee getting a negative result.
    False negatives leave the door open for contagious persons to slip through (i.e., goes to work rather than flagged for isolation)
  • ‘Swab and send’ delays time needed to get to actionable results
  • PCR can remain positive up to 12 weeks after period of infectivity5

#Negative results should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and presence of clinical signs and symptoms consistent with COVID-19
**Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status

SARS-CoV-2 Ag Test

Easy to implement on-site at point of care

  • Room Temperature Storage (36-86°F)
  • Time to result in as quick as 12 minutes
  • Compact and portable instrument with connectivity options

High sensitivity Assay

  • Optimal sensitivity to rapidly detect infectious individuals to prevent onward transmission

Bring the lab to you

  • No need to send employees off site
  • Get the data to inform your decisions on safety and reopening at a micro and macro level
  • COVID-19 testing dedicated to your specific needs

LumiraDx SARS-CoV-2 Ag Test

  • LumiraDx SARS-CoV-2 Ag Test demonstrates high sensitivity at Ct<336
  • LumiraDx SARS-CoV-2 Ag Test can detect 10-30% cases potentially missed by antigen lateral flow tests7-11
  • PCR can still be positive long after period of infectivity, leading to misidentification of infective individuals5
  • SARS-CoV-2 Ag correlates with culture better than PCR for aiding in the identification of infective individuals12
  • LumiraDx SARS-CoV-2 Ag Test provides high detection of infective individuals to break the chain of transmission
VIEW TEST PAGE

LumiraDx Connect

  • LumiraDx Connect is an intelligent, integrated connectivity platform that uses the latest cloud-controlled technology for use with LumiraDx Instrument.
  • LumiraDx Connect ensures easy, secure transfer of results from LumiraDx Instrument to Connect Manager.
  • Can be used with mobile phones, tablets or PCs
VIEW TEST PAGE

We are focused on customer experience and dedicated to getting it right every time.

Inquire now

1: Michael J. Mina, etal., Rethinking Covid-19 Test Sensitivity — A Strategy for Containment, N Engl J Med 2020; 383:e120

2: Report of the „Bundesamt für Gesundheit“ Switzerland 2020 (available upon request)

3: Kohmer et al., 2021. J Clin Med Jan 17;10(2):328.

4: Krüger et al., 2021 (https://www.medrxiv.org/content/10.1101/2021.03.02.21252430v1)

5. www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html

6: Drain PK, Ampajwala M, Chappel C, et al. A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infect Dis Ther. 2021;10(2):753-761.

7: Linares et al, Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms, J Clin Virol. 2020 Dec; 133: 104659

8: Gannon C.K. Mak, Stephen S.Y. Lau, Kitty K.Y. Wong, Nancy L.S. Chow, C.S. Lau, Edman T.K. Lam, Rickjason C.W. Chan, Dominic N.C. Tsang, Evaluation of rapid antigen detection kit from the WHO Emergency Use List for detecting SARS-CoV-2, Journal of Clinical Virology, Volume 134, 2021, 104712, ISSN 1386-6532, https://doi.org/10.1016/j.jcv.2020.104712.

9: Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, Griego-Fullbright C, Burgard C, Fernandez C, Eckert K, Andrews JC, Ren H, Allen J, Ackerman R, Cooper CK. 2021. Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS antigen point-ofcare test. J Clin Microbiol 59:e02338-20. https:// doi.org/10.1128/JCM.02338-20

10: Osterman, A., Baldauf, HM., Eletreby, M. et al. Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. Med Microbiol Immunol 210, 65–72 (2021). https://doi.org/10.1007/s00430-020-00698-8

11. Labcorp EUA – Histogram of Cts, https://www.fda.gov/media/136151/download

12: Andrew Pekosz et al., Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture, Clinical Infectious Diseases, 2021;, ciaa1706, https://doi.org/10.1093/cid/ciaa1706

For use by healthcare professionals only. Products not available in all countries or regions. Available in the USA under FDA Emergency Use Authorization. In the USA, this test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. In the USA, this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

BetterHealthExperiencesOutcomes

Supporting healthier lives, for individuals, communities and wider society

Enabling responsive, personal relationships between patients and care teams.

Controlling and reducing costs to help ease pressure on healthcare budgets.